How similar is similar enough?

Advanced biotherapeutic characterization technologies from Waters help laboratories achieve the standards of regulatory bodies around the world: To produce sufficient analytical and biological evidence of similarity between innovator and biosimilar candidates that will reduce the clinical trial burden for approval. Because whether it's called a biosimilar, follow-on biologic, biogeneric, second-generation mAb, non-innovator protein, or even biobetter, the goal is the same: therapeutic safety and efficacy to improve patient health and wellness.

  • Обзор
  • Детали
  • Похожие страницы
  • Библиотека
  • Методики

Свяжитесь с Waters